What is MoonLake Immunotherapeutics's debt issuances?

MoonLake Immunotherapeutics (MLTX) reported debt issuances of $100M in Q1 2026.

How has MoonLake Immunotherapeutics's debt issuances changed year-over-year?

MoonLake Immunotherapeutics's debt issuances increased by 33.3% year-over-year, from $75M to $100M.

MoonLake Immunotherapeutics MLTX Debt issuances

Debt issuances at other companies

John Wiley & Sons, Inc.WLYB

$265.26M+73.5%

HNIHNI

$188M+45.6%

Lincoln Educational Services CorporationLINC

$33M—

Construction PartnersROAD

$0—

TFX

TeleflexTFX

$0-100%

VestisVSTS

$27M-32.5%

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentFaceAmount.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's debt issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's debt issuances?: MoonLake Immunotherapeutics (MLTX) reported debt issuances of $100M in Q1 2026.
How has MoonLake Immunotherapeutics's debt issuances changed year-over-year?: MoonLake Immunotherapeutics's debt issuances increased by 33.3% year-over-year, from $75M to $100M.